Abstracts presented at ASCO 2017: drug re-challenge and pharmacoeconomics
Could cabozantinib be a successful novel therapy for mCRPC?
Can Merkel cell carcinoma be treated with a cancer vaccine
When should treatment be stopped?
Promising biomarkers to select patients for checkpoint inhibitor therapy in melanoma